Core Viewpoint - The company, Jinkai (Liaoning) Life Science Technology Co., Ltd., specializes in providing custom development and production services for small molecule drug intermediates and a small amount of raw materials for global pharmaceutical companies, with a focus on fluorinated and non-fluorinated CDMO businesses [2][8]. Group 1: Business Overview - The main business involves providing small molecule drug intermediates and limited raw materials for new drug development projects for globally recognized pharmaceutical companies [2][8]. - The company has a significant focus on fluorinated CDMO services, including specialized fluorination agents and other fluorinated products [3][8]. - As of the 2024 annual report, overseas revenue accounts for 61.18% of total revenue, benefiting from the depreciation of the RMB [4]. Group 2: Financial Performance - For the period from January to September 2025, the company achieved a revenue of 488 million yuan, representing a year-on-year growth of 25.96%, and a net profit attributable to the parent company of 103 million yuan, reflecting a substantial increase of 163.24% [8]. - The company has distributed a total of 117 million yuan in dividends since its A-share listing [9]. Group 3: Market Activity - On December 16, the company's stock price fell by 2.50%, with a trading volume of 39.89 million yuan and a turnover rate of 2.15%, resulting in a total market capitalization of 3.896 billion yuan [1]. - The stock has shown no clear trend in major capital inflows, with a net outflow of 4.2829 million yuan today, ranking 27th out of 52 in its industry [5][6].
金凯生科跌2.50%，成交额3988.78万元，近5日主力净流入-520.68万